|Description||NSC12 is an extracellular trap for fibroblast growth factor 2 (FGF2). It binds FGF2 with Kd value of 51 µM and interferes with its interaction with FGFR1 without affecting the ability of FGF2 to bind heparin or heparin sulfate proteoglycans. It also binds several other FGF isoforms and prevents them from forming HSPG/FGF/FGFR ternary complexes. It inhibits FGF-dependent angiogenesis and tumor cell proliferation in vitro and reduces tumor growth in mice. It inhibited the proliferation of different FGF-dependent tumour cell lines, but had no inhibitory effect on FGF-independent tumour cells expressing a constitutively active FGFR1. It was shown to inhibit FGFR phosphorylation, angiogenesis and primary and metastatic tumour growth of FGF-dependent human and mouse cancer cells in vivo. It has significant implications in cancer therapy.|
|Synonyms||NSC-12; NSC 12; NSC12; NSC 172285; NSC-172285; NSC172285; 21-(Hydroxy(bistrifluoromethyl)methyl)pregnane-3,20-diol;Pregn-5-ene-3,20-diol, 21-(2-hydroxy-1,1,1,3,3,3-hexafluoro-2-propyl)-;LS-118618;4,4,4-Trifluoro-1-[(8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-3-(trifluoromethyl)butane-1,3-diol;NSC-12;NSC-172285;NSC172285;(R)-4,4,4-trifluoro-1-((3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-3-(trifluoromethyl)butane-1,3-diol|
|Solubility||10 mM in DMSO|
|Application||NSC12 has significant implications in cancer therapy.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||521.8±45.0 °C | Condition: Press: 760 Torr|
|Density||1.31±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
BLU9931 is a potent and irreversible small-molecule inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 si...
ARQ-087, also known as Derazantinib, is an oral fibroblast growth factor receptor (FGFR) inhibitor with antitumor property. FGFR plays a role in the regulation ...
SU11652 is a cell-permeable and sunitinib-like inhibitor of tyrosine kinase receptor (RTK) and angiogenesis with antineoplastic property. It selectively inhibit...
SSR128129E free acid
SSR128129E free acid is a multi-FGFR blocker with allosteric properties. It inhibits FGFR signaling by binding to the extracellular FGFR domain without affectin...
SKLB610 is a VEGFR inhibitor that potently suppresses human tumor angiogenesis. SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth...
Alofanib, also known as RPT835, is a potent and selective allosteric inhibitor of FGFR2 with potential anticancer activity. Alofanib blocks the extracellular pa...
Debio-1347, also known as FF284 and CH5183284, is an orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and ...
PD-161570 is a selective inhibitor of human FGF-1 receptor tyrosine kinase, with IC50 values to be 40, 262 and 3700 nM for FGFR1, PDGFR and EGFR tyrosine kinase...